Rather like working with committed colleagues than with a company, and we got great data out of the project

 Prof. Dr. Andreas Weigert 

Goethe-University Frankfurt, Faculty of Medicine, Institute of Biochemistry I, Frankfurt, Germany

"We were under considerable time pressure to gain comprehensive information about cytokine/chemokine levels in a mouse model of self-resolving inflammation. To add to our misery, we had only a small number of biological replicates to run the analyses. Thankfully, the team at Sciomics were able to come to our rescue by providing a very prompt analysis, without neglecting to properly communicate the procedure, potential caveats and other details. The whole process was a very satisfying experience, rather like working with committed colleagues than with a company, and we got great data out of the project. I do happily recommend working with Sciomics for targeted proteomics analyses."

Product: scioCD


New article | Anti-cancer activity and mechanism of action of metformin in endometrial cancer cells

| March 2021 | Scientists at Heidelberg University Hospital characterized the protein profile response of an endometrial cell line to Metformin treatment and hyperinsulinemia  with our scioDiscover platform:

"The presented data helps identify potential targets affected by metformin treatment in EC and allows for a better understanding of the mechanism of action of the biguanide drug’s anti-cancer activity.

With the presented data, we contribute to a better understanding of the anti-cancer activity of metformin as well as its underlying mechanism of action in EC cells."

Lange, C. et al. (2021) ‘Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line’, PLoS ONE 16(3):e0248103. https://doi.org/10.1371/journal.pone.0248103 

New article | BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

| Dec 2020 | Scientists at University of Sassari used our scioPhospho  platform to to analyse the synergy of BET and PARP inhibition in Small Cell Lung Cancer Cells:

"Among the I-BET762-associated and combination-associated differentially expressed proteins, 150 were common to both treatment conditions. ... Ranking I-BET762-associated and combination-associated DEPs by their differential expression revealed CHEK2 and PTEN to be among the top-downregulated proteins, whose deficiencies have been associated with HR defects and increased PARPi sensitivity. "

Fiorentino, F. P. et al. (2020) ‘BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells’, International Journal of Molecular Sciences, 21(24). doi: 10.3390/ijms21249595.


New article | Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields

| Feb 2021 | Scientists at Rostock University Medical Center used our scioCD  platform to Corneal Epithelial Cells stimulated with Alternating Current Electric Fields:

"Analysis of the protein array data revealed that the treatment of cells with AC EFs altered the expression of various protein products ... revealed activation of various diverse cellular signaling pathways in which TNF, MAPK, IL17, and PI3K-Akt signaling pathways were significantly impacted ..."

B. S. Kowtharapu et. al., „Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields“, Genes, Bd. 12, Nr. 2, Art. Nr. 2, Feb. 2021, doi: 10.3390/genes12020299.


Corona | Sciomics is fully operational

Dear partners and friends,
We from Sciomics are hoping that you are all safe and well and would like to give you an update on our current activities in these challenging times.

To limit the spread of the COVID-19 virus and to ensure the safety of our employees as well as the continuation of all projects, Sciomics has early implemented preventive actions which have recently been further increased:
- only people critical to the laboratory activity are present on site
- implementation of non-overlapping teams for all on-site activities 
- efficient home office capabilities for all personnel

Through these actions, all our protein and post-translational analysis capabilities remain fully operational and we are able to continue all active projects as well as to begin new studies in the foreseeable future.  
Please feel free to contact us at any time if you have any questions or like to discuss how we may support you best during the current situation as well as in future projects.
As health is the highest good, we wish you all the best for you as well as your families and loved ones.


covid 19 operational v3 web

scioCyto : Cytokine profiling

scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or cell cultur supernatants can be used in this robust assay. The complete analysis services comprises all steps from protein extraction from your samples to a comprehensive study report for interpretation of the data.


  • up to 119 cytokines and chemokines analysed in a single assay
  • robust assay with 8 technical replicates
  • most antibodies available for follow-up studies
  • phosphorylation & ubiquitination status on request

Benefits for your research

  • comprehensive cytokine and chemokine signalling information
  • low sample volumes (10 μL plasma/serum)
  • sensitivity as ELISAs
  • analysis possible from plasma/serum, tissue, cells, supernatants, CSF
  • complete analysis service
    protein extraction > bioinformatic data interpretation

scioCyto analysis process




Plasma samples 

  • Immune system activity
  • Immune response profile
  • Biomarkers

Tissue samples

  • Microenvironment analysis
  • 3D cell culture models
  • Immune signalling
  • Inflammation status

Cell samples

  • Cellular signalling
  • Immune cell activation
  • Growth/stimuli profiling
  • Supernatant analysis


 Need more coverage? Have a look at our scioCD or scioDiscover service!

Contact us


scioCyto target proteins


scioCyto enables a robust profiling of up to 119 cytokines and chemokines in one single assay from minute sample amounts.

scioCyto target cytokines for profiling




CCL1 ,   CCL2 ,   CCL3 ,   CCL4 ,   CCL5 ,   CCL7 ,   CCL8 ,   CCL11 ,   CCL13 ,   CCL14 ,   CCL15 ,   CCL16 ,   CCL17 ,   CCL18 ,   CCL19 ,   CCL20 ,   CCL21 ,   CCL22 ,   CCL23 ,   CCL24 ,   CCL25 ,   CCL26 ,   CCL27 ,   CCL28
C-X-C motif 

CXCL1 ,   CXCL5 ,   CXCL6 ,   CXCL7 (PPBP) ,   CXCL8 (IL-8) ,   CXCL9 ,
CXCL10 ,   CXCL11 ,   CXCL12 (SDF-1) ,   CXCL13 ,   CXCL14 ,   CXCL16 
C motif XCL1
C-X3-C motif CX3CL1


Interferons IFNA1 ,   IFNG ,   IFNL1 ,   IFNL2 ,   IFNL3


IL-1A ,   IL-1B ,   IL-2 ,   IL-3 ,   IL-4 ,   IL-5 ,   IL-6 ,   IL-7 ,   IL-8 (CXCL8) ,   IL-9 ,
IL-10 ,   IL-12p70 ,   IL-12B ,   IL-13 ,   IL-15 ,   IL-16 ,   IL-17 ,   IL-17B ,   IL-17C ,   IL-17F ,   IL-18 ,   IL-19 ,
IL-20 ,   IL-22 ,   IL-23A ,   IL-25 ,   IL-27A ,   IL-28A (IFNL2) ,   IL-28B (IFNL3) ,   IL-29 (IFN-L1) ,
IL-31 ,   IL-32 ,   IL-33 ,   IL-34 ,   IL-36G ,   IL-37

TNFSF4 (CD252) ,   TNFSF5 (CD154, CD40L) ,  
,   TNFSF7 (CD70, CD27-L) ,   TNFSF8 (CD153, CD30-L) ,
TNFSF10 (TRAIL, CD253) ,   TNFSF11 (CD254, OPG-L) ,   TNFSF12 (APO3-L) ,
TNFSF13 (APRIL, CD256) ,   TNFSF13B (BAFF, CD257) ,
TNFSF14 (CD258, HVEM-L) ,   TNFSF18 (AITRL) 

Cytokine / growth factor activity

Colony-stimulating factors (CSF) M-CSF ,   GM-CSF ,   G-CSF
TGF-Family TGFB1 ,   TGFB2 ,   TGFB3
VEGF-Family VEGF165/VEGF121 ,   VEGFA ,   VEGFC

CNTF ,   CRLF2 ,   CYTL1,
FGF2 ,   FLT3L ,
GDF2 ,   GDF15 ,   GRN,
HGF ,   HMGB1 ,
IGF1 ,   INHBA ,
NGF-beta ,
PLF4 ,


Contact us   Overview scio-Cyto


Need more coverage? Have a look at our scioCD or scioDiscover service!

New article | Selective elimination of immunosuppressive T cells in patients with multiple myeloma

| Feb 2021 | Scientists at Heidelberg University Hospital used our scioCD  platform to profile CD8+SLAMF7+ cell cultures:

"High throughput screening of 351 different cytokines and immune proteins in the supernatants of the T cells cultures revealed strong upregulation of IL-6, IL-8, both vital survival factors for myeloma cells, and CXCL5, a chemokine that could enhance the frequency of CD4 Treg, in the cultures containing CD8+SLAMF7+ cells. IL-2 and IL-5 were upregulated in the control cultures without CD8+SLAMF7+ T cells, highlighting a more activated state in the control group and suggestion IL-6 and IL-8 as potential effector cytokines for the suppressive CD8+SLAMF7+ T cells."

Awwad, M. H. S. et al. (2021) ‘Selective elimination of immunosuppressive T cells in patients with multiple myeloma’, Leukemia, pp. 1–14. doi: 10.1038/s41375-021-01172-x.


Neuro-Sys and Sciomics announce Partnership Agreement

Neuro-Sys and Sciomics announce a collaboration to co-develop an unrivaled integrated preclinical solution in neurodegenerative disorders.


Announcement : Neuro-Sys and Sciomics announce a collaboration to co-develop an unrivaled integrated preclinical solution in neurodegenerative disorders.

December 18, 2019 06:57 PM Eastern Standard Time

GARDANNE, France and HEIDELBERG, Germany – The French biotech company Neuro-Sys SAS and the German biotech company Sciomics GmbH today announced that they are joining their R&D forces to study the proteome and the phosphoproteome in preclinical models of Alzheimer’s, Parkinson’s and ALS diseases to investigate the proteomic and phosphoproteomic profile of these disease models. The aim is to better understand the mechanisms involved in the neurodegenerative process and to provide new solutions for characterizing the efficacy and mode-of-action of neuroprotective compounds.
The changes in the proteome (protein level) and phosphoproteome (phosphorylation status of proteins) will be determined by the scioPhospho platform using advanced in vitro models of Alzheimer’s disease (focused on the chronic and the acute toxicity of the beta amyloid oligomers, AβO), Parkinson’s disease (with a specific attention to the mitochondrial disorders), and amyotrophic lateral sclerosis (focused on the hypersensitivity to glutamate stressor). In addition, the inflammatory component will be analyzed (cytokine release profile).
Identified proteomic changes will be correlated with neuronal survival and proteinopathies detected by immunostaining (e.g. hyperphosphorylation of Tau ; alpha-synuclein aggregation ; translocation of TDP-43).
For many years, we have been thoroughly investigating the mechanisms occurring in these neurodegenerative diseases. We have developed advanced in vitro models of these diseases in which the mechanisms and the pathways involved in the process of death are carefully studied through our intensive internal research and partnerships”, said Noelle Callizot, PharmD, Ph.D., Chief Scientific Officer at Neuro-Sys. “We believe that the collaboration with Sciomics is a great opportunity to better understand pathophysiological pathways and to help our partners in the development of new therapeutic approaches.
Over the last decade we have developed an efficient and robust platform for profiling protein levels and phosphorylation status.”, said Dr. Christoph Schröder, Chief Executive Officer at Sciomics. “By a combination of the profound expertise and advanced pre-clinical models of Neuro-Sys with our in-depth protein readout options, we are looking forward to foster novel insights and developments in the important field of neurodegenerative disorders.

Preliminary results are expected to be released early 2020.

About Neuro-Sys

Neuro-Sys is an expert in preclinical in vitro models of neurodegenerative and neurological diseases. It has developed specific models to accurately determine the pharmacological profiling of lead compounds and explore their underlying mechanism of action. With a great team of experts and an innovative proprietary automated medium throughput platform combined with advanced models, it provides reliable results and a unique approach in the neurodegenerative diseases research.
The company’s many loyal pharma and biotech customers around the world are the best testimony to the efficiency and reliability of its solution.

Email : This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone : +33 4 1341 5171

About Sciomics

Sciomics has extensive expertise in the area of biomarker discovery, in vitro as well as in vivo model system characterisation and disease mechanism profiling using its high-content protein and post-translational modification profiling platform in an analysis service setting and for internal research. More than 1,000 proteins are currently analysed by the proprietary fully immuno-based scioDiscover antibody array platform in a single assay with minimal sample requirements. Information on the protein abundance can be combined with the phosphorylation, ubiquitination or methylation status of these proteins. The high-content and high-throughput platform guarantees robust and reproducible results which – due to its immuno-based nature - can easily be translated into validation as well as clinical assays.
The platform’s main applications are the discovery of protein biomarkers, screening and verification of new drug targets, pathway activity profiling as well as drug mode-of-action analysis.

Email : This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone : +49 6221 4294830


New article | Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer

| Jan 2019 | In the article, scientists at Tel Aviv University used our scioDiscover platform to analyse tumor-associated eosinophils in colorectal cancer. The full article is published in Cancer Immunology Research.


Even with a very small amount of tissue below 10 mg, the quality we obtained was exceptional.

 apl. Prof. Dr. rer. nat. Andreas H. Wagner 

University Heidelberg, Medical Faculty, Institute of Physiologie and Pathophysiology, Division of Cardiovascular Physiology, Heidelberg, Germany

"We used scioDiscover for differential protein expression profiling in a mouse model with enhanced aortic aneurysm severity to identify target proteins in the aorta after medical therapy. Even with a very small amount of tissue below 10 mg, the quality of sample preparation and the data we obtained was exceptional. The support and advice was professional, very helpful, and very friendly. We are overall very satisfied with the results and the Sciomics team! "

Product: scioDiscover


"Detailed discussions to design the best possible project plan"


Dr. Annett Böddrich
Max Delbrück Center for Molecular Medicine, Department of Proteomics and Molecular Mechanisms of Neurodegenerative Diseases, Berlin, Germany

"We were very satisfied with the service from Sciomics. Using the ScioDiscover antibody microarray on our biosamples, Sciomics identified genes differentially expressed in Alzheimer’s disease models. From the beginning, they engaged in detailed discussions with us to design the best possible project plan. Because we had only small amounts of material, they went to great lengths to adapt their protocols to our needs. They took a lot of time to answer all our questions and discuss the resulting data. I really can recommend Sciomics. "

Service: scioPhospho protein and phosphorylation profiling service


New article | Protection from ischemia reperfusion injury-induced inflammation and fibrosis in C5aR2-deficient mice

| June 2018 | Complement component 5a receptor 2 (C5AR2) deficient mice are protected from inflammation and fibrosis in response to ischemia reperfusion injury. Our scioPhospho platform supported scientists at the Medical School Hannover to elucidate the underlying mechanism. The data were recently published in Kidney International.


"The quality of the data we have obtained is exceptional."


Prof. Claudio Mauro
Birmingham University, Institute of Inflammation and Ageing, Birmingham, UK

"We have performed an acetylation array on primary T lymphocytes with Sciomics. The quality of the data we have obtained is exceptional. They have a model of collaboration with the team conducting the experiment. This means they generate the data and assist with further analyses of the data. The screening has opened up several exciting ways forward for us."

Product: scioAcetyl protein and protein acetylation profiling service (under co-development with selected partners)



Protein & ubiquitination profiling

scioUbi is a high-content protein expression and ubiquitination level analysis.
With scioUbi you can analyse up to 1,000 proteins in a single assay.



  • Screen for differential ubiquitination status
    in >1,000 proteins in parallel in a single assay
  • 4 technical replicates per sample
  • Comprehensive data analysis and presentation including
    an individualised report
  • Customisation of ubiquitin detection on request

Benefits for your research

  • Two in one: High-content protein expression and ubiquitination level analysis in a single assay
  • Proteins selected for biomedical studies: Central regulators (e.g. mTor, p53), transcription factors, receptors
  • Minimal sample (e.g. tissue or cell culture samples) amounts needed for complete analysis
sciomics scioUbi Ubiquitination And Protein Profiling Biological processes selection of proteins
Biological processes
  sciomics scioUbi Ubiquitination And Protein Profiling Cell Cycle proteins coveredCell cycle: proteins in green are covered by the analysis



Biological effects of

  • protein degradation in health and disease
  • protein activity changes
  • protein interaction alterations
  • drug response (e.g. proteasome enhancers)


  • Interplay between ubiquitination and phosphorylation (see scioPhospho)
  • Neurodegenerative diseases
  • Progression of ageing
  • Cell cycle regulation
  • Proteasome activity
  • Transcriptional regulation
  • p53 pathway regulation
  • Alzheimer pathway regulation


Contact us


Sciomics participates in collaborative clinical trials for the treatment of metaphyseal chondrodysplasia type Schmid (MCDS)

See below for German version

Heidelberg, 12th February, 2018


Multinational consortium has been granted 5.7 Million Euro for the development of novel therapeutic approaches in rare skeletal disorders. Sciomics' expertise with the antibody microarray technology herein serves as a valuable tool for biomarker identification and personalized treatment monitoring.

The biotechnology company Sciomics GmbH, located in Heidelberg, Germany, today announced its participation in the multinational clinical project 'MCDS Therapy'. This five-year collaborative study comprises both world-renowned clinical centres as well as small and medium-sized enterprises in the EU and Australia with a total funding of 5.7 Million Euro. In successive clinical trials, the re-purposing of the drug carbamazepine (CBZ) for the treatment of the skeletal disease metaphyseal chondrodysplasia type Schmid (MCDS) will be investigated. Furthermore, 'MCDS Therapy' encompasses biomarker development and health economics assessment studies to deliver an innovative and affordable therapy for MCDS, along with diagnostic and prognostic tools to personalize the treatment.

MCDS is a skeletal disorder resulting in short stature, abnormally shortened or bowed limbs, chronic pain and decreased mobility. Less than 1 in 100,000 people is affected, which renders the disease a so-called orphan disease. The disease is incurable, and MCDS patients rely on the long-term use of pain therapy and usually undergo numerous orthopaedic surgical interventions to correct knee and hip deformities. This burden in pain and disability leads to poor quality of life and extensive healthcare costs.

CBZ received orphan drug designation by the European Commission for the treatment of MCDS in 2016. 'MCDS Therapy' aims at advancing the re-purposing of CBZ to deliver the first non-surgical therapeutic intervention for MCDS. During the course of the project, an assessment of relevant biomarkers will be incorporated. The aim is to discover novel biomarkers that are directly relevant to CBZ treatment of MCDS which can then be used to monitor therapy and are potentially applicable to a broader group of genetic skeletal diseases or human connective tissue disease in general. 'MCDS Therapy' will use a high-content screening approaches to discover panels of potential biomarkers using samples from both mouse models and patient-derived samples. Herein, Sciomics' antibody microarrays serve as a crucial tool to identify and validate biomarkers for diagnosis, prognosis and personalized therapy.

Sciomics GmbH was founded in 2013 as a spin-off company of the German Cancer Research Centre (DKFZ). 'We are glad to participate in this highly innovative project with our solid expertise in antibody microarrays', states Dr. Christoph Schroeder, CEO of Sciomics. 'Accounting for the hallmarks of our microarray technology, which include high throughput, flexibility, multiplex analysis and robustness, I am convinced that our contribution to this novel treatment option for MCDS will be of great service. Especially for the patients suffering from this severe illness.'

> Download press release as PDF-file



Heidelberg, 12. Februar 2018

Sciomics an klinischen Studien für die Behandlung von Metaphysärer Chondrodysplasie Typ Schmid (MCDS) beteiligt

Multinationales Konsortium mit einem Gesamtbudget von 5,7 Millionen Euro entwickelt neue therapeutische Ansätze für seltene Knochenerkrankungen. Hierbei spielen die Antikörper-Microarrays von Sciomics eine zentrale Rolle bei der Identifizierung von Biomarkern und Personalisierung der Therapie.

Das Biotechnologie-Unternehmen Sciomics GmbH mit Sitz in Heidelberg teilte heute seine Beteiligung an dem multinationalen klinischen Projekt „MCDS Therapy” mit. An dem Kooperationprojekt mit einem Gesamtbudget von 5,7 Millionen Euro über fünf Jahre arbeiten sowohl renommierte klinische Zentren als auch kleinere und mittelständische Unternehmen aus der EU und Australien mit. In mehreren klinischen Studien soll hierbei die Verwendung des Medikamentes Carbamazepin (CBZ) zur Behandlung der Knochenerkrankung Metaphysäre Chondrodysplasie Typ Schmid (MCDS) untersucht werden. Ein wichtiger Teil der Studien ist die Identifizierung und Validierung von Biomarkern für Diagnose, Prognose und personalisierte Therapie sowie gesundheitswirtschaftliche Aspekte, um eine innovative und kostengünstige Therapie für MCDS zu entwickeln.

MCDS ist eine Knochenerkrankung, deren Symptome Kleinwüchsigkeit, verkürzte und gekrümmte Extremitäten, chronische Schmerzen und eine eingeschränkte Beweglichkeit sind. Weniger als eine von 100.000 Personen ist davon betroffen; es handelt sich bei MCDS somit um eine sogenannte „Orphan Disease“. Die Krankheit ist unheilbar; MCDS-Patienten sind somit ihr Leben lang auf Schmerztherapie sowie orthopädische Behandlung angewiesen. Die chronischen Schmerzen und Behinderungen führen bei den Patienten zu einer geringen Lebensqualität und hohen Behandlungskosten.

CBZ hat 2016 die „Orphan Drug Designation“ der Europäischen Kommission für MCDS erhalten. Ziel von „MCDS Therapy“ ist es, mit der Verwendung von CBZ die erste nicht-invasive Therapie für MCDS zu entwickeln.Ein wichtiger Aspekt des Projekts ist die Identifizierung und Validierung von Biomarkern, die eine direkte Relevanz für die CBZ-Behandlung von MCDS haben. Diese könnten für die Therapieüberwachung von MCDS eingesetzt werden und möglicherweise auch auf andere genetisch bedingte Knochen- und Bindegewebserkrankungen übertragen werden. Im Zuge von „MCDS Therapy“ werden sowohl Proben aus Mausmodellen, als auch von MCDS-Patienten untersucht. Hierbei dienen die Antikörper-Microarrays von Sciomics als wichtige Werkzeuge bei der Identifizierung und Validierung von Biomarkern für Diagnose, Prognose und personalisierte Therapie.

Sciomics wurde 2013 als Spin-Off des Deutschen Krebsforschungszentrums (DKFZ) gegründet. „Wir freuen uns sehr, mit unserer langjährigen Microarray-Expertise zu diesem hochinnovativen Projekt beitragen zu können“, sagt Dr. Christoph Schröder, Geschäftsführer der Sciomics GmbH. „Angesichts der Vorteile unserer Antikörper-Microarrays, wie hoher Durchsatz, Flexibilität, hochparallele Analyse und Reproduzierbarkeit, werden wir einen wichtigen Beitrag zu neuen Therapieoptionen für MCDS leisten.”


> Pressemitteilung als PDF


Sciomics GmbH
Dr. Christoph Schröder
Im Neuenheimer Feld 583
D-69120 Heidelberg

Phone: +49 (0) 6221 42948-30
Fax : +49 (0) 6221 42948-34
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Web: http://www.sciomics.de